The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

A.V. D'Amico

Joint Center for Radiation Therapy

Harvard Medical School

Boston

MA 02215

USA

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA. 1997 - 2001
  • Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, USA. 1999 - 2001
  • Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA. 2001
  • Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. 2001
  • Joint Center for Radiation Therapy, Harvard Medical School, and Department of Pathology, Brigham and Women's Hospital, USA. 1999

References

  1. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. D'Amico, A.V., Schultz, D., Silver, B., Henry, L., Hurwitz, M., Kaplan, I., Beard, C.J., Renshaw, A.A. Int. J. Radiat. Oncol. Biol. Phys. (2001) [Pubmed]
  2. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. D'Amico, A. Urology (2001) [Pubmed]
  3. Combined-modality staging for localized adenocarcinoma of the prostate. D'Amico, A.V. Oncology (Williston Park, N.Y.) (2001) [Pubmed]
  4. A practical method to achieve prostate gland immobilization and target verification for daily treatment. D'Amico, A.V., Manola, J., Loffredo, M., Lopes, L., Nissen, K., O'Farrell, D.A., Gordon, L., Tempany, C.M., Cormack, R.A. Int. J. Radiat. Oncol. Biol. Phys. (2001) [Pubmed]
  5. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Fondurulia, J., Chen, M.H., Tomaszewski, J.E., Renshaw, A.A., Wein, A., Richie, J.P. J. Clin. Oncol. (2000) [Pubmed]
  6. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. D'Amico, A., Cormack, R., Kumar, S., Tempany, C.M. J. Endourol. (2000) [Pubmed]
  7. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. D'Amico, A.V., Schultz, D., Loffredo, M., Dugal, R., Hurwitz, M., Kaplan, I., Beard, C.J., Renshaw, A.A., Kantoff, P.W. JAMA (2000) [Pubmed]
  8. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Wu, Y.H., Chen, M.H., Hurwitz, M., Kantoff, P.W., Tomaszewski, J.E., Renshaw, A.A., Wein, A., Richie, J.P. J. Clin. Oncol. (2000) [Pubmed]
  9. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score </= 7. D'Amico, A.V., Wu, Y., Chen, M.H., Nash, M., Renshaw, A.A., Richie, J.P. Cancer (2000) [Pubmed]
  10. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Silver, B., Henry, L., Hurwitz, M., Kaplan, I., Beard, C.J., Tomaszewski, J.E., Renshaw, A.A., Wein, A., Richie, J.P. Mol. Urol (2000) [Pubmed]
  11. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?. D'Amico, A.V., Davis, A., Vargas, S.O., Renshaw, A.A., Jiroutek, M., Richie, J.P. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  12. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Fondurulia, J., Chen, M.H., Kaplan, I., Beard, C.J., Tomaszewski, J.E., Renshaw, A.A., Wein, A., Coleman, C.N. J. Clin. Oncol. (1999) [Pubmed]
  13. Innovative treatment for clinically localized adenocarcinoma of the prostate: the future role of molecular imaging. D'Amico, A.V., Debruyne, F., Huland, H., Richie, J.P. Prostate (1999) [Pubmed]
  14. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. D'Amico, A.V., Renshaw, A.A., Arsenault, L., Schultz, D., Richie, J.P. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  15. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy. D'Amico, A.V., Renshaw, A.A., Schultz, D., Rocha, S., Richie, J.P. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  16. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Renshaw, A.A., Tomaszewski, J.E., Richie, J.P., Wein, A. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  17. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Kaplan, I., Beard, C.J., Tomaszewski, J.E., Renshaw, A.A., Loughlin, K.R., Richie, J.P., Wein, A. J. Clin. Oncol. (1998) [Pubmed]
  18. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Blank, K., Broderick, G.A., Tomaszewski, J.E., Renshaw, A.A., Kaplan, I., Beard, C.J., Wein, A. JAMA (1998) [Pubmed]
  19. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Tomaszewski, J.E., Wein, A. J. Clin. Oncol. (1997) [Pubmed]
 
WikiGenes - Universities